LDN193189 is a highly potent BMP inhibitor, prevents Smad1, Smad5, and Smad8 phosphorylation through inhibition of BMP type I receptors ALK2 (IC50=5nM) and ALK3 (IC50=30 nM). Its inhibitions against ALK4, ALK5, and ALK7 are weak (IC50 >500 nM). As BMP signaling coordinates developmental patterning and has essential physiological roles in mature organisms, LDN-193189 is used to reduce ectopic ossification in a mouse model.
Technical information:
| Chemical Formula: | C25H22N6 C25H22N6 | |
| CAS #: | 1062368-24-4 | |
| Molecular Weight: | 406.48 | |
| Purity: | >98% | |
| Appearance: | Yellow solid | |
| Chemical Name: | 4-(6-(4-(piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | |
| Solubility: | Up to 100 mM in DMSO |
Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.
Reference:
| 1. | Paul B Yu, et al. BMP type I receptor inhibition reduces heterotopic ossification. Nature Med. (2008) 14: 1363-1369. |
| 2. | Cuny GD, et al. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett. (2008) 18(15):4388-92. |
| 3. | Paul B Yu, et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nature Chem Biol. (2008) 4: 33-41. |
Other Information:
Product Specification (pdf)
MSDS (pdf)
